Want to create an interactive transcript for this episode?
Podcast: OncLive® On Air
Episode: Real-World Perspectives on mCRC and GI Neuroendocrine Neoplasms; With RocÃo GarcÃa-Carbonero, MD, PhD
Description: In our conversation, Dr GarcÃa-Carbonero discussed a subgroup analysis from the phase 3 FRESCO-2 trial (NCT04322539), which evaluated fruquintinib (Fruzaqla) in previously treated metastatic CRC (mCRC). She reviewed efficacy outcomes by metastatic site, including liver-only, lung-only, bone, and peritoneal disease. Fruquintinib demonstrated improvements in overall survival and progression-free survival across all subgroups, underscoring its feasibility in later-line settings for patients with mCRC. She also addressed prognostic differences between metastatic sites, noting that all patient groups derived benefit from treatment. Dr GarcÃa-Carbonero also shared findings from PROMETCO, the first international, prospective, real-world study in mCRC, which is examining real-world outcomes fo...